Currently, there are more and more studies that link the role of environmental pollution or ecosystem imbalances with people’s health: exposure to diesel engine smoke and its association with lung and / or bladder cancer or ultraviolet radiation with the appearance of melanomas are some examples. Knowing exactly to what extent each person is exposed is complicated, but there are certain risk factors, such as environmental ones or those relating to lifestyle, which can be modifiable to prevent the appearance of this type of pathology.
This was the idea behind the fourth virtual meeting Greentalks, organized by Gaceta Médica and Muy Interesante, where multidisciplinary experts agreed on a key point: fostering collaboration in networking in order to take advantage of the knowledge of each medical specialty. In this context, exposure to pollution and carcinogens or climate change became the protagonists of the virtual meeting ‘Environmental pollution and oncohematological diseases’, which had the support of Fundamed and GSK.
This networking becomes a fundamental piece when the different exposures to carcinogens can vary according to each person. This singularity is known as exposome, a term explained by Jesús García Foncillas, director of the OncoHealth Oncology Institute and Head of the Medical Oncology Service of the Jiménez Díaz Foundation , who insists on studying different molecular profiles, produced as a result of prolonged exposure to pollution , in order to prevent and anticipate deaths from cancer.
You can see the full talk below
“We have the role of delving into cellular mechanics with the study of the exposome and the development of diseases depending on the person,” Ruano indicated. To develop this analysis, the collaboration of all agents becomes a pillar in research. The director of the Carlos III Health Institute, Raquel Yotti , is committed to the integration of epigenetic and genetic factors with environmental elements that “in a joint and integrated way will be the determinants of diseases.” In this sense, influencing carcinogens and looking beyond diagnosis and treatment is essential for Laura Mezquita, an oncologist at the Spanish Society of Medical Oncology (SEOM) , who is committed to strengthening “the clinical wealth that oncologists can contribute.”
Networking includes all the agents involved and, in this context, Guillermo De Juan, vice president and director of Institutional Relations and Communication at GSK Spain , highlights the commitment of the pharmaceutical company to help improve patient survival through development of new drugs, with a new R&D approach, through immuno-oncology, cell therapies, cancer epigenetics or synthetic lethality, among others, while promoting initiatives that fight against the effects of climate change .
